Related Experiment Video
Updated: Aug 11, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
[Treatment of chronic hepatitis. A comparative study of the effect azathioprine and (+)-cyanidanol-3]
Abstract:
The clinical, biochemical and histological results of the treatment of 2 groups of 8 patients each with chronic hepatitis (persistent or aggressive) treated with azathioprine (100mg daily) or (+)-cyanidanol-3(1.5g daily) are compared. The duration of treatmant was 6 months, with monthly examination during this period. The clinical results were comparable in the 2 groups. Among the liver function tests, (+)-cyanidanol-3 appeared superior in the case of total bilirubin, transaminases and BSP retention and azathioprine was superior as regards reduction of gamma-globulin, IgG and IgM. These different results appear to correspond to their different mechanisms of action. The tolerance was superior in the (+)-cyanidanol-3 group, in which no side effects were observed, whereas in the azathioprine group, treatment had to be temporarily interrupted in 3 patients showing leukopenia and/or thrombocytopenia. We therefore believe that it can be asserted that treatment with (+)-cyanidanol-3 yields results similar to those obtained with azathioprine, but being a non-immunosuppressive therapy is devoid of the severe consequences produced by a decrease in immunity in day-to-day clinical practice.
More Related Videos
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatitis